Dynamic Advisor Solutions LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Dynamic Advisor Solutions LLC lifted its stake in shares of Stryker Co. (NYSE:SYK) by 2.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,990 shares of the medical technology company’s stock after acquiring an additional 67 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Stryker were worth $1,080,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of SYK. Comerica Bank increased its position in shares of Stryker by 2.5% during the fourth quarter. Comerica Bank now owns 130,671 shares of the medical technology company’s stock worth $39,131,000 after acquiring an additional 3,219 shares during the period. Biltmore Family Office LLC increased its holdings in Stryker by 2.7% in the fourth quarter. Biltmore Family Office LLC now owns 1,540 shares of the medical technology company’s stock valued at $462,000 after buying an additional 40 shares during the last quarter. Bell Investment Advisors Inc increased its holdings in Stryker by 7.9% in the fourth quarter. Bell Investment Advisors Inc now owns 612 shares of the medical technology company’s stock valued at $183,000 after buying an additional 45 shares during the last quarter. Bradley Foster & Sargent Inc. CT increased its holdings in Stryker by 0.7% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 58,844 shares of the medical technology company’s stock valued at $17,621,000 after buying an additional 418 shares during the last quarter. Finally, Grayhawk Investment Strategies Inc. purchased a new position in Stryker in the fourth quarter valued at $684,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $353.54 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The company has a market cap of $134.73 billion, a P/E ratio of 39.41, a PEG ratio of 2.73 and a beta of 0.91. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $374.63. The company has a 50-day moving average price of $350.96 and a 200 day moving average price of $343.00.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 earnings per share. Research analysts predict that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.91%. Stryker’s dividend payout ratio (DPR) is presently 35.67%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 190,000 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the transaction, the director now directly owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Ronda E. Stryker sold 190,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the transaction, the director now directly owns 3,316,608 shares of the company’s stock, valued at $1,072,790,023.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 220,068 shares of company stock valued at $71,811,372. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on SYK. Truist Financial dropped their target price on Stryker from $364.00 to $345.00 and set a “hold” rating on the stock in a report on Thursday, August 1st. Needham & Company LLC increased their target price on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $386.00 price objective on shares of Stryker in a report on Wednesday, July 31st. Barclays raised their price objective on Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, BTIG Research raised their price objective on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $379.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.